Werewolf Therapeutics, Inc. (HOWL)
| Market Cap | 535.38M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 27.53M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 26 |
| Last Price | $19.45 |
| Previous Close | $18.31 |
| Change ($) | 1.14 |
| Change (%) | 6.23% |
| Day's Open | 18.42 |
| Day's Range | 18.42 - 19.57 |
| Day's Volume | 48,717 |
| 52-Week Range | 11.23 - 23.99 |
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to ...
- Recently completed upsized initial public offering raising $120.0 million in gross proceeds - - Recently completed upsized initial public offering raising $120.0 million in gross proceeds -
CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics ...
Werewolf Therapeutics (HOWL) stock is doing incredibly well for its first day of trading on the Nasdaq following its IPO. The post Werewolf Therapeutics IPO: HOWL Stock Comes Out Howling on First Day of...
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutic...
After banking $72 million at the start of the year, Werewolf Therapeutics now wants an IPO.
Werewolf Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
About HOWL
Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATORTM platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our molecules, which we refer to as INDUKINETM molecules, are intended to selectively target the tumor microenvironment, ... [Read more...]
| Industry Biotechnology | IPO Date Apr 30, 2021 |
| CEO Daniel J. Hicklin, Ph.D. | Employees 28 |
| Stock Exchange NASDAQ | Ticker Symbol HOWL |
Analyst Forecasts
The average 12-month stock price forecast for HOWL is 26.50, which is an increase of 36.25% from the latest price.